glp 1 agonists microdose THE PCCA BLOG There isn't enough data to
Description
It is a GLP-1 agonist like the other medications in this chapter, and also a glucose-dependent insulinotropic polypeptide (GIP) agonist
10.1152/ajpcell.00194.2015 22 DunlayS
95% CI, 0.89 to 1.17) [28]
doi: 10.1160/TH16-07-0586
From a pharmacokinetic perspective, besides increased gastric emptying, obesity has been suggested to modulate CYP gene expression, and increased fat mass may result in an increased Vd of lipophilic drugs.210,211 The weight loss effects from GLP-1 RA treatment may reverse these changes and alter the pharmacokinetics of co-administered lipophilic drugs by decreasing the Vd (Figure 3)
Expert Opin Drug Discov
